• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AstraZeneca donates Brixham Environmental Laboratory to Plymouth University

AstraZeneca donates Brixham Environmental Laboratory to Plymouth University

December 9, 2013
CenterWatch Staff

AstraZeneca will donate its Environmental Laboratory in Brixham to Plymouth University to ensure the lab continues to serve scientific and research purposes.

Plymouth University plans to use the site to create a global research and education facility. The -university, known for its marine and environmental science experience, also plans to offer commercial innovation opportunities through the facility via the region’s Growth Acceleration and Investment Network (GAIN).

Steve Rumford, head of the environment team at AstraZeneca, said, “We made the decision in October to close our Brixham site as operating an environmental research laboratory is not a core part of AstraZeneca’s strategy. However, our aim has been to ensure the laboratory and its state-of-the-art facilities remain in use for scientific purposes.”

Professor Wendy Purcell, Plymouth University vice chancellor, said, “We have undertaken a number of research projects with AstraZeneca over the years, and we’re very familiar with the specialist facilities available at the Brixham Environmental Laboratory. We are determined to leverage our academic credentials and enterprise mission to further develop the site into an international center of excellence for marine and environmental research. Through this, we hope to support the creation of highly-skilled jobs that underpin sustainable growth in the region.”

The agreement does not include the transfer of AstraZeneca staff or third-party work commitments. AstraZeneca plans to transfer ownership of the lab to the university by the end of April 2014.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing